The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes - PubMed
3 hours ago
- #inflammatory bowel disease
- #vedolizumab
- #real-world study
- VEST is a UK real-world study examining vedolizumab use in IBD patients within routine clinical practice.
- Study included 364 patients (48% male, mean age 48) across 22 centres; 62% had UC, 36% CD, 2% IBD-U.
- One-year persistence rate was 58% overall and 54% for those with active disease at baseline.
- Patients continuing vedolizumab showed significant improvements in quality of life (IBD-Control-8 and VAS scores) at week 14 and 1 year.
- Clinical remission rates at week 14 for active disease patients: 29% CD, 30% UC, 38% IBD-U; similar rates at 1 year.
- Persistence was associated with baseline/post-induction health status but not with disease type, duration, or bio-naïve status.
- Side effects leading to treatment cessation were rare (3%), indicating good tolerability.
- Study concluded vedolizumab demonstrates high persistence, with sustained patient-reported benefits and safety in diverse UK IBD populations.